Receptor Imaging | Mysite 1

Tumor Receptor Imaging

An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas

Theranostics. 2014; 4(9): 893–903. Colorectal cancer is a serious complication associated with inflammatory bowel disease, often...

PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance

Am J Nucl Med Mol Imaging. 2015; 5(4): 379–389. After initial therapy and total resection of glioblastoma multiforme (GBM), 80-90% of...

18 F-FES PET/CT Measurement of ER Suppression during a Phase I Trial of GDC-0810

Clin Cancer Res; 23(12); 3053-60. Purpose: Evaluate 18F-fluoroestradiol (FES) PET/CT as a biomarker of estrogen receptor (ER) occupancy...

A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68 Ga-DOTATOC

Am J Nucl Med Mol Imaging. 2017; 7(2): 53–62. This prospective pilot study provides a dynamic whole body PET/MR image database, clinical...

Synthesis and preliminary PET imaging of of the ROS1/ALK inhibitor lorlatinib

Nat Commun. 2017 Jun 8;8:15761. Lorlatinib (PF-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine...

Specific 18F-FDHT Accumulation in Human Prostate Cancer Models Is Facilitated by Prebinding to SHBG

J Nuclear Med. 2018 Apr;20(2):300-308. Purpose: Tremendous efforts are currently dedicated to the development of novel therapies...

Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a HER3 Peptide

Mol Imaging Biol. 2018 Apr;20(2):300-308. HER3 (ERBB3) is a receptor tyrosine kinase that is implicated in treatment resistance across...

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance

J Nucl Med. 2016 Sep;57(9):1413-9. Purpose: Inhibitors of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of...

HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib

Mol Imaging Biol. 2021 Jun 8. Purpose: Standard therapy for HER2+ breast cancers includes HER2 inhibition. While HER2 inhibitors have...

HER3 Differentiates Basal From Claudin Type TNBC and Contributes to Drug Resistance

Front Oncol. 2020 Nov 20;10:554704. Triple Negative Breast Cancer (TNBC) is an aggressive form of Breast Cancer (BC). Numerous kinase...

Optical Imaging of MET for Enhanced Detection and Characterization of Hepatic Tumors

Theranostics. 2016 Sep 9;6(12):2028-2038. Purpose: To assess optical imaging of Mesenchymal-Epithelial Transition factor (MET) for...

Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions

Theranostics. 2018 May 23;8(12):3380-3391. Purpose: Reporter gene systems can serve as therapy targets. However, the therapeutic use of...

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

Clin Cancer Res. 2015 Mar 15;21(6):1340-7. Purpose: Estrogen receptor (ER) targeting is key in management of receptor-positive breast...

Free SSTR fraction predicts the antiproliferative effect of octreotide in NETs

Cancer Res. 2013 Dec 1;73(23):6865-73. Somatostatin receptors (SSTR) are highly expressed in well-differentiated neuroendocrine tumors...